---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-021560"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T22:59:40.549691+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma enters $112,350 convertible note at 22% interest with 1800 Diagonal Lending

## Summary
- Issued $112,350 convertible promissory note to 1800 Diagonal Lending LLC at a 22% annual interest rate.
- Conversion price is 75% of average lowest trading price over 10 days prior to conversion, with 4.99% beneficial ownership cap.
- Maturity date April 30, 2026; company can prepay at 120% premium within 90 days, 125% from 91-180 days.
- Proceeds from $107,000 purchase price (after $5,350 original issue discount) used for general working capital.
- Events of default include failure to pay, failure to issue conversion shares, and loss of OTC listing.

## SEC filing metadata
- accession: 0001641172-25-021560
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000164117225021560/0001641172-25-021560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000164117225021560/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-021560
- JSON: https://secwatch.observer/filing/0001641172-25-021560.json
- Plain text: https://secwatch.observer/filing/0001641172-25-021560.txt

## Key facts
- Debt Financings
  Propanc Biopharma, Inc. incurred convertible notes of $112,350 at 22% per annum maturing April 30, 2026.
  - Instrument: convertible notes
  - Principal: $112,350
  - Rate: 22% per annum
  - Maturity: April 30, 2026
  - Event: incurrence
  source text: Effective July 25, 2025, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $112,350 (the “Note”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000164117225021560/0001641172-25-021560-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.